A Study of Ketamine in Patients With Treatment-resistant Depression



Status:Completed
Conditions:Depression, Major Depression Disorder (MDD)
Therapuetic Areas:Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - 64
Updated:4/21/2016
Start Date:August 2012
End Date:September 2013

Use our guide to learn which trials are right for you!

A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression

The purpose of this study is to explore the optimal dose frequency of ketamine in patients
with treatment-resistant depression (TRD).

This is a double-blind (patients and study personnel do not know the identity of the
administered treatments), randomized (the drug is assigned by chance), placebo-controlled
(placebo is a substance that appears identical to the treatment and has no active
ingredients), parallel arm study (each group of patients will be treated at the same time).
The study will consist of a screening phase of up to 4 weeks, a 4-week double-blind
treatment phase (Day 1 to Day 29), and a 3-week post treatment (follow up) phase. In the
double-blind phase, patients will receive over 4 weeks either intravenous (IV) infusions of
placebo (2 or 3 times weekly) or IV infusions of ketamine (2 or 3 times weekly). The total
study duration for each patient will be a maximum of 13 weeks.

Inclusion Criteria:

- Be medically stable on the basis of clinical laboratory tests performed at screening

- Meet diagnostic criteria for recurrent major depressive disorder (MDD), without
psychotic features

- Have a history of inadequate response, ie treatment was not successful, to at least 1
antidepressant

- Have an Inventory of Depressive Symptoms-Clinician rated, 30 item (IDS-C30) total
score >= 40 at screening and predose at Day 1

- Inpatient or agreed to be admitted to the clinic on each dosing day

Exclusion Criteria:

- Has uncontrolled hypertension

- Has a history of, or current signs and symptoms of diseases, infections or conditions
that in the opinion of the investigator, would make participation not be in the best
interest (eg, compromise the well-being) of the patient or that could prevent, limit,
or confound the protocol-specified assessments

- Has known allergies, hypersensitivity, or intolerance to ketamine or its excipients

- Is unable to read and understand the consent forms and patient reported outcomes,
complete study-related procedures, and/or communicate with the study staff
We found this trial at
13
sites
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Allentown, PA
Click here to add this to my saved trials
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Centennial, CO
Click here to add this to my saved trials
Charleston, South Carolina 29412
?
mi
from
Charleston, SC
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Hartford, CT
Click here to add this to my saved trials
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
?
mi
from
Marlton, NJ
Click here to add this to my saved trials
?
mi
from
New Haven, CT
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Rockville, MD
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials